Search
forLearn
5 / 801 resultslearn Beta sitsterol
learn Aminobutyric Acid
learn PTD-DBM
learn ABN Complex
Research
5 / 1000+ results
research Associations between transition‐specific stress experience, nocturnal decline in ambulatory blood pressure, and C‐reactive protein levels among transgender men
Stress from being transgender is linked to higher blood pressure at night and more inflammation, which may affect heart health.
research Quantification of the Vitamin D Receptor−Coregulator Interaction
Vitamin D receptor binds similarly to natural and synthetic ligands, affecting gene regulation.
research Acyl-CoA binding protein and epidermal barrier function
ACBP is essential for healthy skin and fur by maintaining the skin's barrier function.
research The Transcriptional Co-Activator cAMP Response Element-Binding Protein-Binding Protein Is Expressed in Prostate Cancer and Enhances Androgen- and Anti-Androgen-Induced Androgen Receptor Function
A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.
research 42761 The elusive BAP1 mutation in pediatric melanocytic tumors
BAP1 mutations are rare in pediatric melanocytic tumors and may develop later in life.
Community Join
5 / 1000+ resultscommunity Interesting new publication suggesting that MPB should be assessed as a early warning sign for type-2 diabetes.
Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community 21M with a nasty case of MPB; Heres what's on my radar for the future.
Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.
community Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community BPC-157 and Angiogenesis. Bro-Science-Execution-Plan
BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.